Outlook Therapeutics Inc
OTLK
View Detailed Chart
0.429USD
+0.039+10.10%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
23.14MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+10.10%
5 Days
-2.34%
1 Month
-18.90%
6 Months
-77.16%
Year to Date
-72.82%
1 Year
-75.18%
View Detailed Chart
TradingKey Stock Score of Outlook Therapeutics Inc
Currency: USD Updated: 2026-02-06Key Insights
Outlook Therapeutics Inc's fundamentals are relatively healthy, with industry-average ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 200 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 5.38.In the medium term, the stock price is expected to trend down.The company has shown very weak stock market performance over the past month, in line with its fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Outlook Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Outlook Therapeutics Inc Highlights
StrengthsRisks
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.
Growing
The company is in a growing phase, with the latest annual income totaling USD 1.41M.
Overvalued
The company’s latest PE is -0.24, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 4.34M shares, decreasing 70.98% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 1.47M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.63.
Analyst Rating
Based on
4
analysts
Buy
Current Rating
5.375
Target Price
+1278.21%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Outlook Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Outlook Therapeutics Inc Info
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.
Ticker SymbolOTLK
CompanyOutlook Therapeutics Inc
CEOJahr (Robert Charles)
Websitehttps://outlooktherapeutics.com/
Related Instruments
+3.66%
+3.14%
+0.93%
+2.01%
+1.82%
+1.60%
-0.95%
+4.49%
+2.10%
+9.92%
+2.76%
+4.15%
+1.79%
+4.17%
+0.72%
+1.10%
+2.46%
0.00%
+0.51%
+0.54%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
68002.200
-1967.930 (-2.81%)
282.580
+22.390 (+8.61%)
2007.660
-44.070 (-2.15%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
